Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major - Wikidata - awgldk - TriplyDB

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

http://www.wikidata.org/entity/Q28208724

about

sameAs

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantum Antiparasitic therapy Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis Sterol biosynthesis is required for heat resistance but not extracellular survival in leishmania Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease SMP-1, a member of a new family of small myristoylated proteins in kinetoplastid parasites, is targeted to the flagellum membrane in Leishmania Leishmaniasis.Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.Leishmaniasis: new approaches to disease control.Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP.Treatment strategies for mucocutaneous leishmaniasis.Leishmaniasis: an update of current pharmacotherapy.Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.Cutaneous ulcer in a man returning from Central America Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.An update on pharmacotherapy for leishmaniasis Epidemiology, pathology and treatment of cutaneous leishmaniasis in taif region of saudi arabia Mechanistic insights into mode of actions of novel oligopeptidase B inhibitors for combating leishmaniasis.Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine to treat leishmaniasis.Therapeutic options for cutaneous leishmaniasis.Distribution frequency of pathogenic bacteria isolated from cutaneus leishmaniasis lesions.β-Nitrostyrenes as Potential Anti-leishmanial Agents.Isolation of bacteria causing secondary bacterial infection in the lesions of Cutaneous Leishmaniasis.Leishmaniasis: clinical syndromes and treatment.Treatment of cutaneous leishmaniasis in travelers 2009.Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers.Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis.The origin recognition complex in human diseases.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Parasitic diseases in travelers: a focus on therapy.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.

P2860

Q27011766-BC4E0C8F-95D5-4D82-88AA-50CC952641A5 Q27668116-26085099-C2EF-48EF-A967-B90EB1FA489F Q28239164-B3709674-FECD-4099-95F1-FB19BE9E2B06 Q28478944-907A358D-5C17-4734-8953-697136335385 Q28542936-1E6E40EA-EBBD-4DFC-97EA-F3278F77B937 Q28544093-0B552B60-141B-4B8C-8EE3-29DED8267F5E Q28727454-F0EAE0D0-D257-407A-8E98-4136A127DF83 Q30275257-6155DF8A-7483-4180-B349-96EEFCEC5882 Q30426102-981FE04B-5195-460E-B04B-368ACB7735ED Q30956007-0B1612D9-408A-4342-B51A-F50EA7A5C981 Q31107638-F3CB8980-1339-4AF9-86F3-F572E716BCE3 Q33786761-C6864421-1B03-48EE-BAD8-A9CFF9DC3CBE Q33813871-3AE0713B-05DE-464E-A7A9-B13E7694B5EC Q33876004-DF26C663-FEE0-4152-A9A0-A0BB7745BB77 Q33929843-42C9DF13-C57D-4FDF-9327-6A9910D90D7A Q34318765-2850AC6F-8128-4EEC-AB0D-A100FC01FFDB Q34654206-C3D0CEF0-7F8A-4CBD-8D1F-F100075AB8B0 Q34733695-44C49745-7888-4F1D-AFA7-48C3C5AC6CEA Q34735206-99CDA841-D906-4F35-BE22-795EBB200A77 Q34945204-F9EA7E3F-6F34-4282-8FC2-0D7A36713E2D Q35047334-7599DD00-065F-4D1C-9F5A-F290AD66C112 Q35102511-89A602D9-369C-4E2C-B191-DD2C76A5FBAC Q35160905-06ED6B62-C464-4335-B602-2D8D489E0E79 Q35606296-4CBEB688-53FF-4ADD-8449-38F11FA90056 Q36192769-B5311ED0-FB42-4548-A6A1-2F1BDD662D54 Q36829628-92A65A8A-6AB3-4099-87E7-21DDE3FB890A Q36908791-7D2766FF-AA5B-43F9-B663-C99554D54311 Q37224367-A2124C26-FDEA-4245-8A25-36FD1950FE38 Q37391621-F7463648-4B19-45BD-83A7-4878B157735F Q37406305-D1EFC228-BAA2-4DE3-9D70-E8505173D6FD Q37428084-3D59BBCD-E03B-464E-B648-4110BE1519AB Q37663500-5B80E4AF-3801-4FBB-816E-100947D92364 Q37720821-2F9F8E43-9B42-46E7-B607-3F67AA64521E Q38105590-E7445806-7420-4C40-93E8-A0359AB5CB8A Q38136837-A23DBD87-D9AD-4F40-BBF8-649E4F95BC75 Q38154629-DED89E1D-613E-4AB2-82A4-3CBC757BE75C Q38156421-83B9D16C-A6F5-42A2-BBC5-360BF2594E57 Q38192001-7C696C48-09DD-4ADB-BB31-1BA664B126B3 Q38205451-4ED0B0C1-7F34-404B-9AA9-153E5B278D48 Q38458645-3ECF4AFB-4274-41AD-9434-9DBB8B0610C6

P2860

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

http://www.wikidata.org/entity/Q28208724

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@ast

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@en

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@nl

type

label

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@ast

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@en

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@nl

prefLabel

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@ast

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@en

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@nl

P1433

Q28208724-5E2C135A-C2DB-42B3-87F5-3B2446CC39EE

P1476

Q28208724-A661DAA4-4D25-460D-B295-CB0663AF7E0D

P2093

Q28208724-2B0467E9-120B-45A2-81B2-E30BC202CD96

Q28208724-4E3E0F85-9B83-409B-9F70-62AF04B2BBFB

Q28208724-8AB60DD0-A9DF-496E-94C7-873C4CEEA65E

Q28208724-926CEE82-FB05-44FB-AAAC-468CE8A73757

Q28208724-C6A1EEEC-768F-4945-B693-2A0CE80B4715

Q28208724-CC474DB5-B9B9-4522-9218-721840BACE4C

P304

Q28208724-1EFB8A43-00A5-40E1-9BAA-47C52A06C140

P31

Q28208724-2A76BEB5-0FC6-420C-90FA-0BCDA1027335

P3181

Q28208724-D88CE7A7-DA55-40E2-8AC1-FC69B3F9CCC2

P356

Q28208724-7BA6B0FE-1492-4488-BDD5-41E8A7AF95E3

P407

Q28208724-0B27C8D8-6BD0-4452-93C2-175D8E4CAA90

P433

Q28208724-B6FDC0FF-7404-43BD-AA17-64EABEDCCA81

P478

Q28208724-3A096E6B-5680-49CA-985F-1D9E373B9E6C

P577

Q28208724-7B375F43-2EF2-41A5-BDC4-B0DD2421F0EB

P698

Q28208724-8E90587A-0E45-449F-98BF-3FE3A7E448B8

P3181

P356

P1433

The New England Journal of Medicine

P1476

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

@en

P2093

Abdulrahman A Alrajhi

http://www.w3.org/2001/XMLSchema#string

Edward B De Vol

http://www.w3.org/2001/XMLSchema#string

Elfaki A Ibrahim

http://www.w3.org/2001/XMLSchema#string

James H Maguire

http://www.w3.org/2001/XMLSchema#string

Mohammad Khairat

http://www.w3.org/2001/XMLSchema#string

Rajab M Faris

http://www.w3.org/2001/XMLSchema#string

P304

891-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3742968

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA011882

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11907288

http://www.w3.org/2001/XMLSchema#string